Acute Lymphoblastic Lymphoma - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 34

Acute Lymphoblastic Lymphoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Acute Lymphoblastic Lymphoma - Pipeline Review, H2 2012', provides an overview of the Acute Lymphoblastic Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Acute Lymphoblastic Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lymphoblastic Lymphoma. 'Acute Lymphoblastic Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Lymphoblastic Lymphoma.
- A review of the Acute Lymphoblastic Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Lymphoblastic Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Lymphoblastic Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Lymphoblastic Lymphoma pipeline depth and focus of Acute Lymphoblastic Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Acute Lymphoblastic Lymphoma Therapeutic Products under Development, Key Players in Acute Lymphoblastic Lymphoma Therapeutics, Acute Lymphoblastic Lymphoma Pipeline Overview, Acute Lymphoblastic Lymphoma Pipeline, Acute Lymphoblastic Lymphoma Pipeline Assessment

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Acute Lymphoblastic Lymphoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Acute Lymphoblastic Lymphoma 7
Acute Lymphoblastic Lymphoma Therapeutics under Development by Companies 9
Acute Lymphoblastic Lymphoma Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Acute Lymphoblastic Lymphoma Therapeutics – Products under Development by Companies 13
Acute Lymphoblastic Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Acute Lymphoblastic Lymphoma Therapeutics Development 15
Bristol-Myers Squibb Company 15
Acute Lymphoblastic Lymphoma – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
Therapeutic Allogeneic Lymphocytes - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Hyper-CVAD + Filgrastim + Nelarabine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 24
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 27
Rituximab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
BMS-906024 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Acute Lymphoblastic Lymphoma Therapeutics - Dormant Products 30
Acute Lymphoblastic Lymphoma – Product Development Milestones 31
Featured News & Press Releases 31
Dec 13, 2011: Immunomedics Announces Results From Phase II Trial Of Epratuzumab At Hematology Conference 31
Dec 11, 2011: Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma 31
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Number of Products Under Development for Acute Lymphoblastic Lymphoma, H2 2012 7
Products under Development for Acute Lymphoblastic Lymphoma – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Bristol-Myers Squibb Company, H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Acute Lymphoblastic Lymphoma Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Acute Lymphoblastic Lymphoma, H2 2012 7
Products under Development for Acute Lymphoblastic Lymphoma – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Customers who bought this item also bought

• Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2013
• Acute Pain - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012
• Acute Heart Failure - Pipeline Review, H2 2012
• Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012